The CBF has labelled and certified further vials of ChAd3 and MVA vaccines for a Phase I Ebola vaccine trial in Dakar (Senegal). The trial is currently led by Pro Souleymane Mboup at the Laboratorie de Bacteriologie-Virologie in Senegal. The two trial vaccines were tested for the first time at the Jenner Institute in Oxford. The ChAd3 vaccine has been developed by GlaxoSmithKline (GSK) and its partners while the MVA vaccine was developed and manufactured through a collaboration between Oxford University, Emergent Biosolutions and GSK and its partners. 

Further trials using these and other vaccines (all to be QP certified at the CBF) are in the pipeline.